NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.
Saved in:
| Title: | NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss. |
|---|---|
| Authors: | Lu S; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Yin Z; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Wu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Department of Stomatology, Peking Union Medical College Hospital, Beijing, China., Sun Y; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Clinical Research for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China., Chen J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.; Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China., Wu LMN; Medpace Inc., Cincinnati, OH, USA., Oblinger JL; Center for Childhood Cancer, Abigail Wexner Research Institute at Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, USA., Blake DC; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Xiu B; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Landegger LD; Department of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA., Seist R; Department of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA., Ho W; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Jones AP; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Muzikansky A; Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Stankovic KM; Department of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA., Plotkin SR; Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chang LS; Center for Childhood Cancer, Abigail Wexner Research Institute at Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, USA., Xu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. lexu@mgh.harvard.edu. |
| Source: | Nature communications [Nat Commun] 2026 Feb 11; Vol. 17 (1), pp. 1148. Date of Electronic Publication: 2026 Feb 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
